GILD Stock Analysis: Buy, Sell, or Hold?
GILD - Gilead Sciences Inc
$130.51
0.93 (0.72%)
▲
5d:
-2.25%
30d:
-5.18%
90d:
-15.95%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
GILD is down 3.1% this week, but smart money is accumulating calls. Top strike: $140 2026-06-18 with 1,808 OI. Call ratio: 65% View Scanner →
Strength: 7.8/10
Get Alerted When GILD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GILD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: GILD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$199.46
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$123.85
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GILD is currently trading at $130.51, which is considered oversold relative to its 30-day fair value range of $130.72 to $138.78. The stock's valuation (Forward PE: 13.4) is in line with its historical norms (14.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This pessimistic expectation contrasts with the company's recent 54.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GILD is in a uptrend. The price is currently testing key support at $129.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $157.96 (+21.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GILD is in a uptrend. The price is currently testing key support at $129.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $157.96 (+21.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$130.72 -
$138.78
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.9% below Wall St target ($157.96)
Trading Range Analysis
30-Day Trading Range
$130.72 -
$138.78
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$129.00
Resistance Level
$137.50
Current Trend
Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.38
Wall Street Target
$157.96
(+21.9%)
Revenue Growth (YoY)
4.4%
Earnings Growth (YoY)
54.8%
Profit Margin
31.0%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
13.4 vs 14.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$125.69
(-3%)
2-Year Target
$121.92
(-6%)
3-Year Target
$118.26
(-9%)
3-Yr Target (if PE normalizes)
(PE: 13→15)
$129.92
(+0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 17.94 | Current EPS (TTM): $7.36
Bull Case
$191.13
(+48%)
Analyst growth 31.6%, PE expands to 19.7
Base Case
$173.76
(+34%)
Market implied 31.6%, PE stable at 17.9
Bear Case
$89.80
(-31%)
Severe decline -20.0%, PE contracts to 15.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.4 to 14.7
Stabilization Target:
$142.35
(+9.9%)
PE Expansion Potential:
+9.9%
Share & Embed Analysis
Last updated: May 18, 2026 10:36 AM ET
Data refreshes hourly during market hours. Next update: 11:36 AM
Data refreshes hourly during market hours. Next update: 11:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GILD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew D Dickinson
SELL
3000 shares
2026-04-15
Johanna Mercier
SELL
3000 shares
2026-04-15
Andrew D Dickinson
SELL
3000 shares
2026-03-16
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1210 | 62 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$253 | 65 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$218 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$352 | 60 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 63 BUY |
Advanced GILD Option Strategies
Professional options setups generated by AI based on today's GILD price and gamma walls.
